Immunotherapy and non-small cell lung cancers

 

  • Letizia Laera UO Oncologia “Sandro Pitigliani”, Nuovo Ospedale di Prato “Santo Stefano”, Azienda USL Toscana Centro, Prato, Italy.
  • Silvia Novello AOU S. Luigi Gonzaga, Università degli Studi di Torino, Torino, Italy.
Keywords: lung cancer, immunotherapy, programmed cell death-1 (PD-1) inhibitors, programmed cell deathligand 1 (PD-L1) inhibitors

Abstract

Lung cancer is the leading cause of cancer mortality, and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Immunotherapy has brought a paradigm shift to the treatment of NSCLC. Immune checkpoint inhibitors have emerged as one of the main new therapeutic options for patients with advanced NSCLC. This brief review focuses on analyzing the biological rationale and early clinical data available concerning immunotherapeutic strategies, and more specifically, programmed cell death-1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors.
Published
2017-12-15